Who
Michael Jay Ross
Director
Company insider
Files Form 4 as: Director, TRex Bio; Director, Xilio Therapeutics; Director, Deciphera Pharmaceuticals; Director and 10% owner, Sutro Biopharma; Director, Catabasis Pharmaceuticals; Director and 10% owner, X4 Pharmaceuticals; Director, Ophthotech.
In numbers
- Trades disclosed
- 86
- Buys
- 1
- Sells
- 0
- Bought
- $5.0M
- Sold
- $0
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 23 Oct 2013
- Last trade
- 8 Oct 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Oct 2026filed 8 Oct 2026 | TRXB TRex Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,200 at $0.00 | filing |
| 21 Oct 2021filed 25 Oct 2021 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,400 at $0.00 | filing |
| 11 Jun 2019filed 13 Jun 2019 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —21,776 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —131,683 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —64,815 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,835,270 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —11,097,596 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —5,462,550 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —17,533 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —106,019 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —52,183 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —9,217,015 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —6,683,697 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —9,155,794 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —194,786 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —141,249 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —193,492 at $0.00 | filing |
| 1 Oct 2018filed 1 Oct 2018 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code C | —943 | filing |
News
Insider Buying: X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Acquires $11,868.00 in StockXFOR · tickerreport.com · 22 Oct 2026
0 headlines in the last 90 days name Michael Jay Ross; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.